EMA Issues Statement on Brexit
The agency offers its official comment following the UK's historic vote last week to leave the European Union.
In the wake of the dramatic result of Thursday’s UK referendum on Brexit, the London-based European Medicines Agency (EMA) issued an official statement today to the press. In an email sent to Applied Clinical Trials in response to a request for comment on the agency's potential relocation, the EMA gave the following statement:
We respect the UK citizens’ decision to no longer be a part of the European Union.
The people in the UK have taken their vote and it is now up to the UK government to decide how to act upon the outcome of the referendum.
Article 50 of the Treaty on the Functioning of the EU foresees the procedure to be followed in case a Member State notifies the European Council of its decision to withdraw from the Union. No country has ever decided to leave the EU, so there is no precedent for this situation. It is too early to foresee the implications of this decision and we will be in close contact with the EU institutions. When we have concrete information, we will share it with our stakeholders.
EMA will continue with its work with the goal to protect human and animal health and ensure access to medicines that are safe, effective and of good quality.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
